Date: 2018-01-25
Type of information: Services contract
Compound: ATOR-1015
Company: Alligator Bioscience (Sweden) Theradex Oncology (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: services contract
Action mechanism:
- bispecific antibody/immune checkpoint inhibitor. ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and was created with Alligator’s unique bispecific technology.
Disease:
Details:
- • On January 25, 2018, Alligator Bioscience announced that it has appointed Theradex Oncology, a global contract research organization with extensive expertise in oncology clinical development, as CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The study is expected to commence in the second half of 2018.
- The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark.
- Production of clinical trial material has already been completed and the final clinical trial authorization enabling activities required for study initiation will be completed in H1 2018.
Financial terms:
Latest news:
Is general: Yes
